Company ProfilePremium

Sensera Limited

Company Profile Analysis

Ticker: SE1.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Sensera Limited - Company showcase

Year Founded & Workforce

2016

11 Employees

Sensera Limited logo

Sensera Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Sensera Limited Overview

Commentary: Headcount was never disclosed in a form that can be verified for these years. Qualitatively, the Abiomed transaction required at least 90% of Sensera Inc. employees to transfer to Abiomed as a completion condition (S&P Capital IQ summary of the asset purchase agreement, Nov 2021), which implies that the operating workforce left the group on completion, leaving only directors and outsourced company-secretarial support.

Sensera Limited was an ASX-listed micro-cap that set out in 2016 to build a vertically integrated Internet of Things sensor business, spanning custom MEMS (micro-electro-mechanical systems) fabrication in the Boston area through to wireless location-awareness chips, modules and software from its Berlin subsidiary nanotron. Its MEMS foundry served demanding medical, industrial and aerospace customers, most notably Abiomed's Impella heart-pump programme and Harvard's Wyss Institute, while nanotron supplied precision real-time location systems for livestock monitoring (Smartbow/Zoetis), mining safety and industrial tracking. Repeated capital raisings, high customer concentration, persistent losses and the COVID-19 shock forced a strategic retreat: nanotron was sold to Inpixon in 2020 and the MEMS business to its largest customer, Abiomed, in a 2021–22 asset sale. Stripped of operations, Sensera became a cash shell and was removed from the ASX Official List in October 2023. It survives today as an unlisted corporate vehicle with no disclosed business activity.


Company's own description (latest available)

In its final operating-period disclosures, Sensera described itself as an Internet of Things sensor solution provider (ASX quarterly update, 18 October 2021). Earlier boilerplate, used from 2019 onward, characterised the company as an IoT solution provider delivering sensor-based products that turn real-time data into meaningful information, action and value, designing and manufacturing hardware and software across the vertical technology spectrum, from MEMS structures and sensors to wireless networked systems and software that together form an IoT platform (Market Index company snapshot; Business Wire release on fibre-optic assembly capability). In 2017–2018 the company's language emphasised "end-to-end sensor solutions" and "sensor-based location and situation awareness" (ASX announcements, 14 December 2017 and 28 March 2018).

The latest annual report available through aggregators is the 2022 Annual Report (FY ended 30 June 2022) (AnnualReports.com). Post-divestment, data providers describe the group as having completed the sale of the MicroDevices business and continuing to investigate new business opportunities (Moomoo company profile; ROIC.ai), and as having no significant operations (MarketBeat).

Independent characterisation

Over its operating life (2016–2022), Sensera ran two businesses with very different economics:

  1. MicroDevices (MEMS) — Sensera Inc., Massachusetts. A small, specialised MEMS foundry and design house performing an estimated 85–90% of the semiconductor process in-house at its Boston-area facility (TMT Analytics initiation, as reported by FNArena, 28 March 2018). It manufactured custom micro-structures and sensors to customer specification, including pressure sensors, electrochemical sensors, microfluidic devices and moulds, micromirror arrays for telecommunications and LiDAR, fibre and electro-optic assemblies, and infrared emitters (Simply Wall St company description). Quality certifications included ISO 9001 and ISO 13485 (medical devices) (Business Wire release on fibre-optic assembly). This was a build-to-print and co-development model: non-recurring engineering (NRE) revenue during design and qualification, followed by recurring production revenue once a customer's device entered volume manufacture.

  2. IoT Solutions — nanotron Technologies GmbH, Berlin (Aug/Sept 2017 to Oct 2020). A venture-backed, revenue-stage provider of location chips, smart modules and location software for precise real-time positioning combined with wireless data communication, protected by several international patents (nanotron press release, 14 September 2017). Key verticals were dairy/livestock monitoring (sensor-equipped ear tags via Smartbow, later part of Zoetis), mining personnel and vehicle safety (e.g., a 2019 partnership with Meglab), and industrial and rail safety (a European rail safety project) (Stockhead 2018; Pitt Street Research Nov 2019; SmallCaps FY2020 results coverage).

Revenue model and mix

Revenue typeDescriptionDisclosure status
Product sales (MEMS)Volume production of custom MEMS sensors/devices for OEMs (e.g., Abiomed)Mix % n/d
NRE / development services (MEMS)Design, prototyping and qualification fees; the company flagged expected additional NRE revenue in Oct 2021Mix % n/d
Product sales (IoT)Location chips, modules, tags and anchors (nanotron)Mix % n/d
Software / SaaS (IoT)Location software; the company was building a software back-end to convert mining products into recurring SaaS (Stockhead, Aug 2018)Mix % n/d
LicensingNo material licensing revenue disclosed—

In 2018 the company highlighted a strategic move from a product-sale (capex) model toward a solution-service (opex) model (Sensera acquisition presentation, Aug 2018, weblink.com.au).

Value-chain position, customers and end-markets

Value-chain position: Mid-stream component and subsystem supplier. In MEMS, Sensera sat between materials/equipment vendors and medical-device or instrument OEMs; in IoT, it supplied silicon, modules and software to system integrators and solution vendors (Smartbow, mining safety integrators).

Customer types: Medical device OEMs (Abiomed), academic/translational research institutes (Harvard Wyss Institute), diagnostics developers (NanoDX, which moved to a different design in Oct 2021), agtech solution providers (Smartbow/Zoetis), mining-safety integrators (Meglab), rail-safety system developers.

End-markets: Medical technology (cardiac support, microfluidics, diagnostics), agriculture/livestock, mining, rail and industrial safety, telecommunications/LiDAR optics, aerospace and defence (TMT Analytics noted supply to medical, industrial and military verticals).

Current state: No end-markets served; the company has no operating business.

Strategy

Historical strategic themes (2017–2020)

From company announcements and investor materials:

  1. Vertical integration "from MEMS structures to sensors to IoT platforms." The 2018 acquisition presentation framed the nanotron combination as creating an end-to-end IoT provider, citing a MEMS total addressable market of about US$1 billion.

  2. Shift from product (capex) sales to solution-service (opex) models, including a planned SaaS back-end for mining products (acquisition presentation 2018; Stockhead Aug 2018).

  3. Commercialisation through channel partners such as Smartbow/Zoetis and Meglab (TMT Analytics coverage, Mar 2018; Pitt Street Research, Nov 2019).

  4. Gross margin target model of ~60% and operating breakeven (TMT Analytics; SmallCaps FY2020).

  5. Diversification away from Abiomed concentration (ASX quarterly, Oct 2021).

Initiatives in the last 24 months (Oct 2024 – Oct 2026)

No strategic initiatives, transactions, partnerships, ESG commitments or cost programmes have been publicly announced by Sensera Limited in the last 24 months. As an unlisted public company, it has no continuous-disclosure obligation to the market, though it remains subject to ASIC annual reporting obligations depending on its size and shareholder base. The last stated strategic intent was to investigate new business opportunities (Moomoo; ROIC.ai).

Medium-term targets and guidance

None current. Historical guidance included FY2018 revenue of US$6.25–7.25m and FY2019 revenue of $10.5–11.5m (Stockhead 2018).

Products & Services

No products are currently offered. The historical catalogue is set out below by segment.

MicroDevices (Sensera Inc.) — historical

Product / serviceDescription & capabilitiesTarget customersLaunch / versionPricing
MEMS pressure sensorsMiniature pressure sensing structures; supplied for Abiomed's Impella heart-pump platform (two products using Sensera technology by mid-2018)Medical device OEMsProduction ramp from c. 2018—
Electrochemical sensorsMEMS-based chemical/biochemical sensing elementsDiagnostics, environmental, industrial——
Microfluidic devices and mouldsMoulds for manufacturing polymeric membranes assembled into microfluidic devices (Harvard Wyss Institute)Bioanalytical, medtech, research institutesc. 2019—
Micromirror arraysMEMS mirror arrays for telecommunications and LiDARTelecom optics, LiDAR developers——
Fibre / electro-optic assemblies; optical benchPrecision fibre-optic and micro-optical assemblies for medical, industrial and aerospace systemsMedtech, industrial, aerospaceCapability expanded c. 2018–2019—
Infrared emittersMEMS IR sources for gas sensing and spectroscopyInstrument makers——
Foundry / NRE servicesDesign, prototyping, qualification, wafer processing (85–90% in-house)OEMs and start-ups (e.g., NanoDX)OngoingProject-based NRE

Sources: Simply Wall St description; Business Wire release; SmallCaps (Wyss); Stockhead (Abiomed products); FNArena/TMT Analytics (in-house process share).

IoT Solutions (nanotron) — historical

Product / serviceDescription & capabilitiesTarget customersLaunch / versionPricing
Location chipsChirp-based RF ranging/positioning silicon enabling precise real-time positioning with concurrent data communicationModule makers, integratorsPre-2017 heritage—
Smart modulesIntegrated radio/location modules for tags and anchorsIntegrators (agtech, mining)——
Location software / RTLS platformReal-time location engine; updated livestock location and tracking software released under Sensera ownershipLivestock health, mining, industrialUpdated version c. 2019–2020—
Livestock ear-tag sensing (with Smartbow/Zoetis)Sensor chips in cow ear tags feeding an analytics system; roadmap based on several thousand dairy farms for FY19–FY20 deploymentDairy and beef farmsSmartbow selling from Jan 2018Multi-million-dollar supply deal; terms n/d
Mining safety solutionsPersonnel/vehicle proximity and location; planned SaaS back-endMining operators (via Meglab etc.)2018–2019Intended recurring SaaS
Rail safety projectLocation technology tested and approved for next phase in a European rail safety projectRail operators/integratorsFY2020—

Sources: nanotron press release (2017); Stockhead (2018); SmallCaps (FY2020; software release); Pitt Street Research (2019). The nanotron product line has been part of Inpixon (later restructured) since October 2020.

Financial Narrative

Data availability statement

Sensera's statutory accounts (Appendix 4E and annual reports for FY2017–FY2022, half-year Appendix 4D reports and Appendix 4C quarterlies) were lodged with ASX, but full line-item figures could not be retrieved from accessible sources for most years. The tables below include only figures that could be traced to a named source. All other cells are n/d. No figures have been estimated. Sensera's functional/presentation currency was the US dollar.

Income statement

Notes and sources:

  • FY2017 and FY2018 revenue and losses: Stockhead (Aug 2018), reporting revenue rising from $1.2m to $6.35m and the loss widening 29% to $7m from $5m; FY2018 guidance of US$6.25–7.25m reaffirmed (Stockhead, 2018).

  • FY2019 guidance of $10.5–11.5m (70% growth): Stockhead (Aug 2018).

  • FY2019/FY2020 revenue of 14.7m/16.9m and FY2020 ~60% gross margin (second half and Q4): SmallCaps FY2020 results coverage. These are inconsistent in scale with USD-denominated company guidance and quarterlies and are treated as unconfirmed-currency figures.

  • FY2020 Q4 revenue reported as 3.3m (SmallCaps, currency unconfirmed).

  • No dividends were ever declared (loss-making throughout).

Later periods (continuing MicroDevices operations)

Source: Sensera ASX Quarterly Update and Appendix 4C, 18 October 2021; Stockhead, 18 October 2021.

Aggregator snapshot (Simply Wall St, last reported earnings to 31 December 2021, trailing basis): revenue US$3.0m, cost of revenue US$1.6m, gross profit US$1.3m, other expenses -US$0.25m, earnings US$1.6m. The positive earnings figure most likely reflects non-operating items (such as gains or holdback releases related to divestments) rather than operating profitability; this interpretation is analytical, not disclosed. IBISWorld reports total revenue (including other revenue) of about $875,000 for 2023, consistent with a shell earning mainly interest and incidental income.

Balance sheet

Sources: Stockhead (Aug 2018) for FY2017/FY2018 cash. Cash of $4.5m at 31 December 2017 (Stockhead, 2018). The company carried secured loans before October 2020; Inpixon disclosed that part of the nanotron purchase price was used by Sensera to repay outstanding loans and release security over nanotron's assets (Inpixon 10-K FY2020). Lender identity and quantum are n/d. Goodwill arising on the 2017 nanotron acquisition would have been derecognised on the 2020 sale.

Cash flow and capital raised

Equity raised mapping (calendar events to fiscal years ending 30 June): IPO A$10m (Dec 2016, FY2017); A$4.6m (Aug 2017) plus ~A$7m (Nov 2017) = ~A$11.6m (FY2018); A$8.83m (Aug–Sept 2018, FY2019); A$9.4m plus SPP (Oct 2019, FY2020). Sources: Stockhead (Aug 2018); Sensera acquisition presentation; Pitt Street Research (Nov 2019). Cumulatively, Sensera raised roughly A$40m of equity in under three years, against disposal proceeds of US$8.7m (nanotron, gross) and US$7.5m (MicroDevices, headline).

Ratios

All return ratios were negative in loss-making years (FY2017–FY2021 operating basis), but precise values cannot be computed without balance sheet data.

Revenue CAGR

On press-reported figures, revenue grew from 1.2m (FY2017) to 6.35m (FY2018), a single-year increase of about 429%, driven overwhelmingly by the consolidation of nanotron from August/September 2017 and the start of Abiomed production. A multi-year CAGR from FY2018 to FY2020 cannot be computed reliably because the FY2019/FY2020 press figures appear to be in a different currency from FY2018.

Commentary on trends, inflections and drivers

Growth by acquisition, not organic scale. The FY2018 revenue step-up came from acquiring nanotron rather than from organic MEMS growth; TMT Analytics' FY2018 forecasts attributed roughly 64% of expected revenue to nanotron (US$4.35m of US$6.85m). This made Sensera's top line dependent on a German IoT business it later had to sell.

Persistent losses and cost overruns. The FY2018 loss widened to about $7m, which the company attributed to a blow-out in general and administrative costs plus higher R&D (Stockhead, Aug 2018). Management repeatedly guided to a gross margin target model of around 60% and to operating breakeven by the end of FY2019 (TMT Analytics, Mar 2018); gross margins did approach 60% in H2 FY2020, but operating breakeven was not achieved on a sustained basis.

Serial dilution. Each raise was priced lower: the August 2018 entitlement was set at A$0.11, below any previous trading price, and by FY2020 the shares traded at about A$0.034 (SmallCaps). CEO Ralph Schmitt publicly acknowledged that the company should have raised double the amount at the time of the nanotron deal to avoid repeated returns to investors (Stockhead, Aug 2018).

COVID-19 inflection (FY2020). The pandemic primarily hurt the IoT Solutions business while MicroDevices benefited from its role in medical markets; management responded with restructuring and cost cuts (SmallCaps FY2020).

Shrinking to a single-customer foundry (FY2021–FY2022). After the nanotron sale, continuing revenue ran at roughly US$0.5–0.6m per quarter, heavily dependent on Abiomed. In Q1 FY2022, sensor sensitivity issues halved revenue potential, a key customer (NanoDX) chose a different design, and cash fell to about US$1.1m with quarterly operating outflows of about US$1.2m (ASX quarterly, Oct 2021). This left roughly one quarter of cash runway, which in our assessment made a sale of the MEMS business to Abiomed, its anchor customer, close to the only viable option.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentLegal entityContentsStatus

MicroDevices

Sensera Inc. (Massachusetts)

Custom MEMS fabrication, sensors, microfluidics, micro-optics, IR emitters, fibre/electro-optic assemblies

Sold to Abiomed (agreed Nov 2021; completed 2022)

IoT Solutions

nanotron Technologies GmbH (Berlin)

Location chips, modules, RTLS software; livestock, mining, rail/industrial safety

Sold to Inpixon (completed 6 Oct 2020)

Corporate

Sensera Limited (Australia)

Listed holding company, treasury, governance

Continuing (shell)

Segment Revenue

SegmentFY2018FY2020

MicroDevices revenue (USD Mn, TMT Analytics forecast for FY2018 only)

2.5—

IoT Solutions revenue (USD Mn, TMT Analytics forecast for FY2018 only)

4.35—

MicroDevices revenue (as reported in press, currency unconfirmed, M)

—6.8

Revenue by Segment (%)

MetricFY2020

MicroDevices share of group revenue (%, derived from press figures)

40

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Margin Analysis (%)

MetricFY2017FY2018FY2019FY2020FY2021

Revenue (as reported in press, M; FY2017–FY2018 consistent with USD guidance)

1.26.35———

Revenue (SmallCaps, currency unconfirmed, likely AUD, M)

——14.716.9—

Revenue guidance midpoint (M, FY2018 USD; FY2019 press)

—6.7511.0——

Gross margin (%)

———60—

Net loss (M, press, currency per source)

-5.0-7.0———

Dividends per share

00000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement

MetricQ4 FY2021Q1 FY2022

Quarterly revenue (USD K)

633505

Cash receipts from customers (USD K)

—408

Net operating cash outflow (USD K)

—1,191

Closing cash (USD K)

—1,146

Financial Analysis

MetricFY2017FY2018

Cash & equivalents (M, press)

4.02.0

Balance Sheet

MetricFY2017FY2018FY2019FY2020FY2021

Equity raised (AUD Mn, gross, per press)

10.011.68.839.4—

Dividends paid

00000

Buybacks

00000

Segment Overview — MicroDevices

SegmentPrimary production locationPrincipal customer geographies (inferred from named customers)

MicroDevices

Massachusetts, USA

United States (Abiomed, Danvers MA; Harvard Wyss Institute, Boston; NanoDX)

IoT Solutions

Berlin, Germany

Europe (Smartbow, Austria; European rail project), plus mining customers (Meglab, Canada)

Corporate

Melbourne, Australia

None (holding company)

Capital Markets

Metric1-year

Share price return (%)

n/d (unlisted since Oct 2023)

Share Price

Metric201720182020

Representative share price (AUD, press-reported points)

0.4050.120.034

Valuation Multiples

MultipleSensera

P/E

Not meaningful (no operations; unlisted)

Firm Details

FirmDateView

TMT Analytics

Mar 2018

Initiation; expected gross margins above 60% and positive operating earnings by end-FY2019 (FNArena)

Pitt Street Research

Nov 2019

DCF valuation cut to A$0.40–0.42 from A$0.50–0.58 per share (FNArena)

Current consensus

—

None; no coverage

Analyst Conclusions

Management guidance and consensus

No guidance has been issued since the company ceased operations, and there is no analyst consensus. Management's last stated intention was to investigate new business opportunities.

Bull-case arguments

  1. Residual cash plus contingent proceeds could exceed the last quoted market cap. The two disposals generated about US$16m in headline consideration; if a meaningful portion remains after debt repayment and costs, a distribution or wind-up could return value relative to the ~A$6.2m last valuation (residual cash n/d).

  2. Clean shell for a new business. With operations, staff and secured debt gone, the vehicle carries limited legacy liabilities and could host a new venture.

  3. Possible tax-loss value for an acquirer that can satisfy Australian loss-recoupment tests.

Bear-case arguments

  1. Delisting removes most strategic optionality. An unlisted shell has little appeal as a backdoor-listing vehicle, and relisting would require full ASX admission compliance.

  2. Cash likely depleted. Cash was only US$1.146m in October 2021 with heavy burn; post-sale proceeds may have been absorbed by transaction costs, liabilities and ongoing overheads.

  3. Track record. Roughly A$40m raised, two businesses sold for a combined ~US$16m headline, and a ~95%+ share price decline from 2017 highs.

Catalysts and monitorables (next 12 months)

  • Any notice to shareholders of a capital return, members' voluntary liquidation or deregistration.

  • ASIC record changes (officeholder changes, financial report lodgements, deregistration applications).

  • Any announcement of an acquisition or new business injection.

  • Confirmation of the outcome of the Inpixon holdback and any Abiomed post-completion adjustments.

Analyst verdict

Sensera Limited is no longer an investable listed company and should be treated in any coverage universe as a delisted, non-operating shell. Its story is a compact case study in the difficulties of building a vertically integrated hardware IoT business from an ASX micro-cap base. The 2016 thesis, combining a niche Massachusetts MEMS foundry with Berlin-based location-awareness silicon and software to sell end-to-end sensor solutions, was coherent on paper, but it required more capital than the company could ever raise on acceptable terms. Four equity raisings in three years, each at a lower price, funded an acquisition-driven revenue jump without delivering operating breakeven, and management itself conceded the nanotron deal had been under-funded.

Operational execution was not the only problem; structural concentration was decisive. The IoT business depended on a few channel partners whose deployments were disrupted by COVID-19, while the MEMS business depended overwhelmingly on Abiomed. When Abiomed-related sensor sensitivity issues halved quarterly revenue potential in late 2021, and a diversification customer moved to another design, cash runway shrank to roughly one quarter. Selling the foundry to its anchor customer for US$7.5m was rational under those conditions, as was the earlier US$8.7m sale of nanotron to Inpixon, but both disposals crystallised value well below the capital shareholders had committed.

Since 2022, the entity has had no business, minimal governance and, since October 2023, no listing. The only remaining questions are whether residual cash and any contingent proceeds will be returned to shareholders, whether the shell will be used for a new venture, or whether it will be wound up. None of these outcomes has been publicly disclosed. For institutional purposes, the appropriate classification is "delisted – no active coverage", with residual interest limited to former shareholders monitoring ASIC records and direct company communications for a capital return or liquidation.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleTenureBackground

Jonathan James Tooth

Non-Executive Chairman

Start date n/d

n/d from verified sources

Simon Peeke

Non-Executive Director (investor/company contact in 2021)

Start date n/d; listed as company contact on the Oct 2021 quarterly

—

Mark Pryn

Company Secretary

—

Associated with the outsourced secretarial office at 440 Collins Street (inferred from address)

Executive Leadership Team

NameRoleTenureNotesSource

Matt Morgan

Founding Chairman (later role transition announced Nov 2017)

c. 2016–2017/18

Chairman at time of Schmitt's MD appointment

ASX announcement 14 Dec 2017

Ralph Schmitt

CEO (from Nov 2017); Managing Director (from 14 Dec 2017); Executive Director

Nov 2017 – completion of Abiomed sale (2022)

Expected to step down from executive and director duties on completion of the Abiomed sale

ASX 14 Dec 2017; S&P Capital IQ Nov 2021

Mr Garrison (first name n/d)

Chief Financial Officer

From 18 Dec 2017; end date n/d

Described as having 19 years as a public-company CFO

ASX announcement 14 Dec 2017

Tim Stucchi

Chief Operating Officer

n/d – 2022

Expected to become an Abiomed employee on completion

S&P Capital IQ Nov 2021

Dr Jens Albers

CEO, nanotron Technologies GmbH

Continued post-2017 acquisition until Oct 2020 sale

Subsidiary CEO

nanotron press release 2017

Major Shareholders

Holder categoryDetail

Institutional ownership

Low; some institutions that joined the Nov 2017 raise reportedly exited quickly, citing insufficient free float to build positions (Stockhead, Aug 2018)

Shares on issue

~414 million (ROIC.ai)

Competitive Landscape

Competitors by Segment

SegmentCompetitorTypeRelative positioning vs Sensera

MEMS foundry / medical MEMS

Teledyne DALSA (Teledyne Technologies)

Large-cap MEMS foundry

Far greater scale and capacity

MEMS foundry

Silex Microsystems

Pure-play MEMS foundry (Sweden)

Larger, broader process portfolio

MEMS foundry

X-FAB (MEMS)

Listed specialty foundry

Much larger, automotive/industrial focus

MEMS foundry

Atomica (formerly IMT)

US MEMS foundry

Similar niche, larger

Medical pressure sensors

TE Connectivity (sensor solutions)

Diversified

Broad medical sensor catalogue

Medical pressure sensors

Amphenol (NovaSensor)

Diversified

Established medical MEMS pressure supplier

MEMS sensors (micro-cap peer)

MEMSIC (now private)

MEMS sensor maker

Higher volume, consumer/auto

RTLS / location (nanotron)

Decawave (now Qorvo)

UWB location silicon

Industry standard UWB; far greater scale

RTLS / location

Zebra Technologies

RTLS systems

Enterprise-scale incumbent

RTLS / location

Ubisense

RTLS systems

Industrial RTLS specialist

Mining safety / location

Strata Worldwide, Becker Mining (examples)

Mining safety systems

Domain incumbents

Livestock monitoring

Allflex/MSD Animal Health (SCR), Afimilk, Nedap

Agtech

Integrated cattle-monitoring incumbents

Competitor Detail

MetricSensera (FY2018)

Revenue

~US$6.35m

Revenue growth

~429% (acquisition-driven)

Operating margin

Negative

Recent Developments

The company is unlisted and dormant from a public-disclosure standpoint. Aggregator pages (MarketBeat, last updated July 2025; Simply Wall St; ROIC.ai) continue to show stale pre-delisting data and confirm no significant operations.

Company Snapshot

11

Employees

2016

Founded

Carlton, Australia

Headquarters

SWOT Analysis

Strengths

  • Clean exit from operations: Both businesses were sold for cash (US$8.7m gross to Inpixon in Oct 2020; US$7.5m to Abiomed, announced Nov 2021), removing operating cash burn.
  • Validated technology at exit: The MicroDevices business was bought by its largest customer, Abiomed, which itself was then acquired by J&J for ~US$16.6bn, an indirect validation of the MEMS capability.
  • Debt reduction: Part of the nanotron proceeds were used to repay secured loans and release security (Inpixon 10-K FY2020).
  • Established corporate vehicle: An Australian public company with an existing shareholder register (~414m shares), auditor (Grant Thornton) and registry (BoardRoom).
  • Low fixed costs: Registered office is a serviced company-secretarial address (440 Collins Street).
  • Historical margin progress: Gross margin near the ~60% target in H2 FY2020 (SmallCaps).

Weaknesses

  • No operating business: Zero sales from operations post-divestment (ROIC.ai).
  • Unlisted: Removed from the ASX Official List on 24 Oct 2023, eliminating liquidity for shareholders.
  • Severe historical value destruction: About A$40m of equity raised in 2016–2019 versus a last quoted market cap of ~A$6.2m.
  • Thin governance: Last disclosed board of two non-executive directors plus a company secretary.
  • Limited disclosure: No public reporting since delisting can be located.
  • Historical customer concentration: Abiomed issues alone halved Q1 FY2022 revenue potential.

Opportunities

  • Capital return to shareholders: Any residual cash from the asset sales and holdback could be distributed (status n/d).
  • Reverse takeover / injection of a new business into the existing corporate shell (stated intent to investigate new opportunities).
  • Voluntary winding-up to crystallise remaining value efficiently.
  • Possible relisting if a substantial new business were acquired (would require full re-compliance with ASX admission rules).
  • Tax losses: Accumulated losses could hold value, subject to continuity-of-ownership and similar-business tests (amount n/d).
  • Recovery of any contingent amounts (e.g., the US$0.75m Inpixon holdback, if not already settled).

Threats

  • Cash erosion: Ongoing audit, registry and compliance costs reduce any residual value.
  • Shareholder illiquidity and apathy: Without a market, shareholders have little leverage or exit.
  • Regulatory deregistration risk if ASIC obligations lapse.
  • Post-completion claims: Warranty or indemnity claims under the Inpixon SPA or Abiomed APA could absorb residual funds (no such claims publicly reported).
  • Opportunity cost: Delisted shells rarely attract quality acquisition targets.
  • Information asymmetry: Shareholders depend on direct communications rather than public filings.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Jul 2025MarketBeat profile refreshed, still showing no significant operations and stale A$6.21m market capConfirms dormancy
31 Oct 2023CHESS subregister closed; holdings moved to issuer-sponsored ASX Notice 1088.23.10Shares no longer tradable on-market
25 Oct 2023ASX publishes cessation notice ASX Notice 1088.23.10Formal record of delisting
24 Oct 2023Removed from ASX Official List (LR 17.11) ASX Notice 1088.23.10End of public listing
FY2023Total revenue (incl. other) ~$875k reported by IBISWorldResidual income only
22 Dec 2022J&J completes acquisition of Abiomed J&J press releaseFormer Sensera MEMS operations now within J&J MedTech
1 Nov 2022J&J announces ~US$16.6bn Abiomed acquisition Press coverageContext for buyer of Sensera's MEMS business
FY20222022 Annual Report lodged (latest available) AnnualReports.comLast full-year accounts
~Apr 2022Scheduled release date of US$0.75m Inpixon holdback (18 months post-closing) Inpixon 10-K FY2020Potential cash inflow; outcome n/d
2022Completion of MicroDevices sale to Abiomed Moomoo; ROIC.aiGroup becomes a shell
31 Jan 2022Long-stop date for Abiomed conditions S&P Capital IQDeal certainty milestone
22 Nov 2021Abiomed asset purchase agreement (US$7.5m) announced; MD Schmitt to step down on completion; COO Stucchi to join Abiomed S&P Capital IQ; GlobalDataStrategic exit
18 Oct 2021Q1 FY2022 Appendix 4C: revenue US$505k; cash US$1.146m; shares fall ~25% ASX; StockheadLiquidity crisis signal
Oct 2021Abiomed backlog unfulfilled due to sensor sensitivity issues; later mitigated ASX quarterlyOperational risk materialised
Early Oct 2021NanoDX chooses a different design StockheadLoss of diversification customer
Q4 FY2021Quarterly revenue US$633k ASX quarterlyBaseline continuing revenue
6 Oct 2020nanotron sale to Inpixon completed Inpixon 10-KExit IoT Solutions
Aug 2020FY2020 results: MicroDevices resilient, ~60% gross margin in H2, rail project advances SmallCapsMargin improvement amid COVID
2020Updated livestock location/tracking software released by nanotron SmallCapsProduct refresh
25 Nov 2019Pitt Street Research cuts valuation to A$0.40–0.42 from A$0.50–0.58 FNArenaLower-margin sales mix and revenue delays
Oct 2019A$9.4m raise plus SPP Pitt Street ResearchWorking-capital relief
2019Meglab mining partnership Pitt Street ResearchMining channel
2019Harvard Wyss Institute collaboration SmallCapsMedtech validation
Aug 2018FY2018 results and A$8.83m entitlement/placement at A$0.11 StockheadThird raise since IPO
28 Mar 2018TMT Analytics initiates coverage ASX announcementResearch visibility
2018Smartbow agreement extended with cost-reduction roadmap StockheadAgtech volume pathway
14 Dec 2017Schmitt appointed MD; new CFO appointed ASX announcementLeadership reset

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

1 chart
Revenue by Segment (%): MicroDevices share of group revenue was 40% in FY2020.
Sensera Limited — Revenue by Segment (%)
Series (%)FY2020
MicroDevices share of group revenue40

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. ASX Online, Notice 1088.23.10, "Cessation of an approval – ASX Code: SE1", 25 Oct 2023 (asxonline.com)
  2. Sensera Limited, ASX announcement, "Sensera appoints Managing Director and new CFO", 14 Dec 2017 (wcsecure.weblink.com.au)
  3. Sensera Limited, ASX announcement, "Initiation of Research Coverage on Sensera by TMT Analytics", 28 Mar 2018 (wcsecure.weblink.com.au)
  4. Sensera Limited, Acquisition Presentation (2018) (wcsecure.weblink.com.au)
  5. Sensera Limited, Appendix 4E (FY2018) (wcsecure.weblink.com.au)
  6. Sensera Limited, Quarterly Update and Appendix 4C, 18 Oct 2021 (wcsecure.weblink.com.au)
  7. Inpixon, Form 10-K FY2020 (Note 8, Nanotron Acquisition) (sec.gov)
  8. Inpixon, Form 10-K FY2021 (Note 6) (sec.gov)
  9. nanotron Technologies, "Sensera acquires nanotron Technologies", 14 Sept 2017 (nanotron.com)
  10. S&P Capital IQ via Inknowvation, "Abiomed agreed to acquire all the assets and business from Sensera, Inc. for $7.5 million", Nov 2021 (inknowvation.com)
  11. GlobalData, Abiomed Inc deals (globaldata.com)
  12. Johnson & Johnson, "Johnson & Johnson Completes Acquisition of Abiomed", 22 Dec 2022 (jnjmedtech.com)
  13. Stockhead, Sensera third capital raising coverage (Aug 2018) (stockhead.com.au)
  14. Stockhead, "Internet of Things play Sensera announces $9m cap raise, unveils $7m loss" (Aug 2018) (stockhead.com.au)
  15. Stockhead, Smartbow deal coverage (2018) (stockhead.com.au)
  16. Stockhead, "Tech Top 5: Sensera drops 25% off the back of Q1 4C filing", 18 Oct 2021 (stockhead.com.au)
  17. SmallCaps, "Sensera posts strong full-year revenue figures despite COVID-19 disruptions" (FY2020) (smallcaps.com.au)
  18. SmallCaps, "Sensera secures 'revenue generating' deal with Harvard University" (smallcaps.com.au)
  19. FNArena, TMT Analytics initiation summary, 28 Mar 2018 (fnarena.com)
  20. FNArena, Pitt Street Research, "Funding Boost For Sensera", 25 Nov 2019 (fnarena.com)
  21. BioSpace / Business Wire, "Sensera Expands Precision Fibre Optic Assembly Capability" (biospace.com)
  22. Market Index, SE1 company profile (marketindex.com.au)
  23. Moomoo, SE1 company profile (moomoo.com)
  24. ROIC.ai, SE1.AX (roic.ai)
  25. Simply Wall St, ASX:SE1 (simplywall.st)
  26. MarketBeat, ASX:SE1 (marketbeat.com)
  27. AnnualReports.com, Sensera (annualreports.com)
  28. IBISWorld, Sensera Limited company profile (img1.ibisworld.com)
  29. CB Insights, Sensera (2001 Series A, Massachusetts) (cbinsights.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.